In multiple oncology updates, GSK logged major progress in blood cancer and lung cancer while an earlier amyotrophic lateral sclerosis attempt was scrapped. On the blood cancer front, GSK agreed to acquire global rights to Chimagen’s tri-specific T-cell engager for multiple myeloma, with the asset expected to enter Phase I trials in 2027. The deal structure, framed as a TCE that engages T cells while binding two tumor-associated antigens, signals GSK’s continued push beyond approved bispecifics and into more complex multi-target approaches. In lung cancer, GSK also received fresh registrational momentum for Jideytro (zidesamtinib), with a 94% objective response rate in a ROS1-positive, TKI-naive cohort. At the same time, Novartis ended development of its Phase 2 ALS candidate VHB937/lifonebart, according to reporting that development was scrapped after the Phase 2 results. For investors and clinical teams, the split message is clear: capital and internal priority continues to shift toward assets with credible response signals and scalable development pathways, while less competitive trials get shut down quickly.